Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 9/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311508 | 0.83 | GABRA1 (0.47) | CYP3A4MAPTERN1PADI4 | |
| SCHEMBL3966986 | 0.78 | CYP3A4 (0.42) | ARCYP3A4MAPTERN1KIF11 | |
| SCHEMBL29397237 | 0.78 | CYP3A4 (0.42) | ARCYP3A4MAPTERN1KIF11 | |
| SCHEMBL14553808 | 0.76 | GABRA1 (0.40) | ARKIF11 | |
| SCHEMBL29957571 | 0.75 | ERN1 (0.48) | ARCYP3A4MAPTERN1PADI4 | |
| SCHEMBL1678780 | 0.75 | ERN1 (0.48) | ARCYP3A4MAPTERN1PADI4 | |
| SCHEMBL4650198 | 0.74 | CYP3A4 (0.44) | CYP3A4MAPTERN1PADI4 | |
| SCHEMBL8111349 | 0.73 | ALDH1A1 (0.39) | ARCYP3A4NFKB1 | |
| SCHEMBL14553803 | 0.72 | KIF11 (0.37) | KIF11 | |
| SCHEMBL4580995 | 0.72 | ERN1 (0.45) | CYP3A4MAPTERN1PADI4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101094827-B | Benzene compound having two or more substituents | DAIICHI SANKYO CO LTD | 2012-06-13 | — | — | CN | disclosed |
| US-7923573-B2 | Benzene compound having 2 or more substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-12 | — | — | US | disclosed |
| US-20080255111-A1 | Tissue Factor Production Inhibitor | SANKYO COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| CN-101119747-A | Tissue factor production inhibitor | SANKYO CO (JP) | 2008-02-06 | — | — | CN | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| CN-101094827-A | Benzene compound having two or more substituents | SANKYO CO (JP) | 2007-12-26 | — | — | CN | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1764075-A1 | TISSUE FACTOR PRODUCTION INHIBITOR | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255111-A1 | Tissue Factor Production Inhibitor | PTAFR, PLAT, TFPI | AR 625/4885CYP3A4 3582/4885MAPT 1662/4885 |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | AR 97/4885CYP3A4 233/4885MAPT 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.